{"id":213200,"name":"NEUROCRINE BIOSCIENCES, INC.","slug":"neurocrine-biosciences-inc","state":"CA","country":"United States of America","description":"Drug discovery and development.","totalSpending":850000,"filings":18,"yearlySpending":[{"year":2021,"income":10000},{"year":2022,"income":200000},{"year":2023,"income":200000},{"year":2024,"income":200000},{"year":2025,"income":240000}],"issues":[{"code":"MMM","display":"Medicare/Medicaid"},{"code":"HCR","display":"Health Issues"},{"code":"BUD","display":"Budget/Appropriations"}],"firms":["CAPITOL COUNSEL LLC"],"lobbyists":["AARON COHEN","JEFFREY CARROLL","MICHELLE MATHY","LUKE HATZIS","JOHN MARTIN","JOSEPH EANNELLO","CHARLES MICHAELS","KAREN STONE"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE"],"sampleDescriptions":["Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treat","Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treat","Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treat","Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treat","Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treat"]}